- 5th ARM Annual Cell & Gene Therapy Investor Day – April 27, Boston (US)
- Investment for Advanced Therapies Summit – May 3, London (UK)
- International Society for Cellular Therapy (ISCT) – May 3-6, London (UK)
Valbonne, France, April 25, 2017, 5.45pm CEST
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, today announces that Stéphane Boissel, CEO of TxCell, will present in upcoming cell therapy conferences.
Mr. Boissel will present an update on TxCell’s ENTrIA CAR-Treg platform at the 5th Alliance for Regenerative Medicine (ARM) Annual Cell & Gene Therapy Investor Day which will be held on April 27, 2017 in Boston (US). The TxCell presentation will be coupled with an interview by Joshua Schimmer, MD, Managing Director and Senior Biotech Equity Research Analyst at Piper Jaffray & Co. The presentation and interview will take place at 5:00pm local time (Harborside Room).
Mr. Boissel will also be participating to a panel discussion entitled “Biotech Perspective: The opportunities of cell & gene therapy and why now?” at the Investment for Advanced Therapies Summit which will be held on May 3, 2017 in London (UK). This panel discussion will take place at 9:15am local time.
In addition, Mr. Boissel and other members from TxCell will attend the International Society for Cellular Therapy (ISCT) 2017 Annual Meeting which will be held on May 3-6, 2017, in London.